NOVEL PEPTIDE DIAGNOSTIC REAGENT AND KIT FOR DETECTION OF RICKETTSIOSIS

Abstract: The present invention relates to a novel peptide, diagnostic reagent and kit for detection of rickettsiosis, more closely for detection of tick borne Rickettsia helvetica. The peptide comprises the amino acid sequence AAPSGSNVEWRNPDNGNYGYVTPNKTYR from the 17 kDa outer membrane protein. Furthemore, the invention relates to a vaccine against rickettsiosis comprising said peptide.

Description: 1 Novel peptide diagnostic reagent and kit for detection of rickettsiosis Background of the invention The present invention relates to a novel peptide, diagnostic reagent and kit for detection of rickettsiosis, more closely for detection of tick borne Rickettsia helvetica. Furthermore, the invention relates to a vaccine against rickettsiosis. Phylogenetically, life on earth can be devided into three major groups or kingdoms; the eucaryots, the eubacteria and the archea. Plants and higher organisms are the eucaryotes while the archea consist of bacteria adapted to extreme environments like hot springs, extreme saline's or the necessity to be able to use methane as carbon source in its catabolic processes. The vast majority of bacteria and the so called blue-green algae are the eubacteria. Of these a few (i.e. Rickettsiae and Chlamydiae) are so specialised that they are obligate intracellular parasites. The closest relatives to the Rickettsiae have been found in genetic evolutionary studies, and have been shown to in a far prehistoric time to be developed to become parasites or symbionts that live inside an other cell as an organelle like the mitochondria. The genus Rickettsiae have until recently been considered to consists of three groups of strictly intracellular bacteria, namely the typhus (TG), the spotted fever (SFG) and the scrub typhus (STG) groups. The classification into species is based on the geographical distribution, arthropod hosts, intracellular location, structure of envelopes, conditions for cultivation and multiplication in chicken embryos, and serological patterns. The TG includes the species R. prowazekii and R. typhi. The members of TG are found mainly in a cytoplasmatic location. Another common trait is the serological cross-reactivity in the Weil-Felix agglutination of Proteus OX19. The TG Rickettsiae occur in scattered locations worldwide and are transmitted to man by lice or fleas. The SFG Rickettsiae are mainly 2 transmitted by ticks and about 20 different species of SFG have been described so far. The species definition of SFG has been based on their serotype as determined by the complement fixation test, the toxin neutralization test in mice, the cross-immunity test in guinea pigs, or the microimmunofluore- scence test (MIF) . However, the serological differentiation of newly isolated strains are difficult, because of a significant cross-reactivity among the recognized SFG Rickettsiae. The third group of Rickettsiae, the scrub typhus group, consists of only one described species, Orientia tsutsugamushi. This species occurs naturally in southern and south-eastern Asia and is transmitted by mite larvae (Leptotrombidium spp.). Furthermore, differences in the structure of the cell envelope and the ribosome sequences to those of the other groups have been recorded. European ticks have been shown to harbor spotted fever Rickettsiae such as R. helvetica in Switzerland, R. slovaca in Russia and R. conorii in France. The fact, that the clinical significance of rickettsial infections cannot be overestimated, has recently been emphasized. Many studies have shown that the signs and the symptoms of rickettsial diseases may differ widely. This is valid for e.g. Rocky Mountain "Spotless" Fever, where the clinical findings are very similar to that of Lyme disease, but where the serological evaluation suggests an infection with R. rickettsii . Another example, is the study of a new rickettsial agent, "ELB", where the definitive clinical diagnosis was murine typhus. Extended investigations have now shown that the "ELB- agent" is a distinct rickettsial species with the proposed name R. felis. 3 Treatments of such infection are today almost exclusive effected by antibiotics or chemoterapeutic drugs. The most common problem with antibiotic treatment is ecological disturbances of the normal flora. A second, often more difficult, problem in treatment of bacterial infections caused by intracellular slow growing bacteria is that of obtaining high enough concentration of the drug at long time enough to kill bacteria in stationary phase of growth. Present therapies for rickettsial infections are antibiotic treatments with chloramphenicol, tetracycline's and occasionally rifampicillin. Diagnosis of rickettsial infection can be made either by cultivation of the organisms or by diagnosis of body fluid from infected individuals, the latter being preferred because cultivation of Rickettsiae is often very difficult and hazardous. For the extreme pathogenic Rickettsiae, not found in Europe, such as R. prowazekii (lice borne spot typhus), R. rickettsii (Rocky mountain spotted fever) and Orientia tsutsugamushi (Scrub tyfus) diagnostic reagents have been described. See, for example, US 7429936 which describes a recombinant protein for diagnosis of R. rickettsii. This protein can also be used to vaccinate humans against Rocky mountain spotted fever. In Journal of Clinical Microbiology, Jan 1997, p 243-247, the present inventors have shown that 1.7% of Scandinavian Ixodes ricinus ticks were positive for rickettsial DNA. Ticks are known to be the most common arthropod reservoirs and vectors of SFG Rickettsiae. Hitherto, Rickettsia are not known to be endemic or epidemic among humans or animals in Scandinavia. The 16S rRNA gene from the isolated strain was amplified and sequenced, and a 1,380 bp sequence from this gene was compared with those of previously described rickettsial species. The result was a 100 % homology with R. helvetica. 4 Species of the genus Rickettsia are closely related and the genetic differences between their 16S rRNA genes are only 2%. For example, 1 1 nucleotides differentiate this isolate from R. conorii, a species endemic in southern Europe and phylogenetically, the most closely related characterized spotted fever Rickettsia, and furthermore the only Rickettsia that has been found in I. ricinus so far. In comparison with R. prowazekii, which is less related and belongs to the typhus group, this strain differs in 25 nucleotide positions. The RFLP pattern of the citrate synthetase gene improves the discrimination between Rickettsiales. The RFLP pattern obtained for the new strain, compared to those of known type strains, is most similar to that of SFG but distinctly different from the published pattern of R.helvetica . According to the nucleotide sequencing results, the detected Rickettsia sp. should be classified as a spotted fever (SFG) Rickettsia. Furthermore, the RFLP pattern suggests that the strain should be regarded as a subtype of R. helvetica. Summary of the invention The present inventors have indications that the Rickettsia found in I. ricinus ticks are pathogenic for humans. Therefore, there exists a need of diagnosis and treatment of rickettsiosis in Scandinavia. An object of the invention was to enable accurate diagnosis of rickettsial infection in Scandinavia. Another object was to provide effective treatment of infected individuals. These and other objects are accomplished according to the invention. Thus, in a first aspect the invention relates to a peptide comprising the amino acid sequence as shown in Sequence Listing No. 1. The peptide is obtained from natural sources, or produced by synthetic or recombinant means. 5 In a second aspect, the invention relates to a diagnostic reagent comprising the above peptide or immune response generating parts or variants thereof for detecting rickettsiosis, especially for detection of infection with Rickettsia helvetica. The diagnostic reagent may be free or bound to lipids or carbohydrates. In a third aspect, the invention relates to a diagnostic kit comprising the above diagnostic reagent which is in the form of a solution or bound to a solid phase. In one embodiment of this aspect, the diagnostic kit comprises a labelled anti-Ig antibody for detection of mammalian IgA, IgG or IgM antibodies against an antigen (ie. the above diagnostic reagent) from R. helvetica. The kit is preferably designed for conventional assay formats like ELISA, EIA, RIA, IRMA etc. The mammalian antibodies used as samples are collected from body fluids such as serum, blood, cerebrospinal fluid, tear fluid, seamen or sweat. In a further embodiment of this aspect, the kit comprises a labelled T cell recognizing agent for detection of rickettsiosis, especially for detection of cellular immune response against an antigen (ie. the above diagnostic reagent) from R. helvetica. In this case, the kit is designed as, for example, a conventional Immuno Spot Assay. In a fourth aspect, the invention provides a vaccine comprising the above peptide or immune response generating parts or variants thereof for treatment of rickettsiosis. The treatment comprises administring, to an individual in need thereof, the vaccine in a suitable adjuvant in a pharmacologically effective amount to develop an immune response in said individual which protects said individual against rickettsiosis. Detailed description of the invention The typical clinical picture during rickettsiosis is high fever, headache and rash. Depending on which rickettsial species that causes the disease the 6 clinical feature could also include lymfadenopathia, myalgia, arthralgia and some forms present with neurological, renal and cardiac problems. The symptoms of the disease can vary from mild to severe and the duration will usually last for 2-3 weeks. The rareness of the disease, and the variety of symptomes complicate the diagnosis. Similar clinical pictures can appear during the course of some non-rickettsial bacterial and viral infections like meningococcemia, measles, typhoid fever, bacterial meningitis, secondary syfilis, leptospirosis, relapsing fever, infectious mononucleosis and rubella. If no rash occurs at all, all kinds of febrile illnesses have to be concerned. Rickettsioses have also the inclination to become a latent infection, a hypothesis proven for R prowazekii, a discovery for which Henri Nicolle was awarded the 1928 year Nobel Prize in Physiology and Medicine. Even for other rickettsial species, a similar latent infection has been postulated (Woddword, 1953, 1997). Such smouldering infection could after some years lead to severe sequelae. Isolates of Rickettsiae of unknown pathogenicity have a tendency to be considered non-pathogenic for human. During the last years a number of such "non-pathogenic" Rickettsiae have been proven to cause different diseases and is therefore reevaluated as pathogenic. Our hypothesis is that if the primary infection is mild, and therefore rarely or not at all become diagnosed, and still progresses into a latent infection causing serious sequelae these infections and organisms will become one of the most urgent to study. Serological assays are the simplest diagnostic tests to perform, since serum can readily be sent to a reference laboratory. The more specific immunogenic reactions one can perform the the more specific will the test become and less crossreactions occur. The immunogenic quality of the bacteria are mainly associated with the structures exposed on the surface of the organism. Of such structures two groups are available. l :One is the outer-membrane proteins, OMPs, and 2: The other is the LPS (lipo-poly-saccaride) as the Rickettsiae are Gram-negative bacteria. The LPS approach have been used 7 for almost a century in the Weil-Felix reaction but is very unspecific. According to the invention, the OMP 17 kDa protein was used. The gene coding for this protein was amplified with the two specific primers in a standard PCR assay. The amplified PCR product was sequenced by using the Sanger dideoxy chain termination method and the result are given in Sequence Listing No. 2. This sequence was translated into amino acids, and a specific peptide was chosen corresponding to 28 amino acids from baspairs 277-360. This 28 amino acids antigenic peptide could be produced either by purification from cultured species closely related to Rickettsia helvetica expressing this peptide in the 17 kDa OMP, from recombinant organisms with a vector having an inserted sequence comprising bp 277-360 according to Sequence Listing No. 2 or variants thereof, or by pure chemical synthesis. The invention will now be described more closely below in association with some non-limiting Examples along with the enclosed Sequence Listings and Figure. Example 1: Amplification and sequencing of rickettsial gene The following specific primer pair was constructed; 17up 5 ' AAAATTCTAAAAACCAT 17LOW 5 CAATTCACAACTTGCC From a collection of free living I. ricinus ticks, total DNA was isolated after trituration and addition of 300 μL low salt TE buffer ( 10 mM Tris pH 7.4, 1 mM EDTA, 10 mM NaCl), 20 μL 20% sodium dodecyl sulphate (SDS) and 5 μL 10 mg/ml Proteinase K (Boehringer, Mannheim). The mixture was incubated at 55°C for 1 h and heated for 10 min at 95°C. Extraction was performed twice with saturated phenol, once with a mixture of phenol/ chloroform and finally once with chloroform. The DNA was precipitated overnight by addition of 1/ 10 vol. 4 M sodium acetate and 3 vol. 99% ethanol and collected by centrifugation at 20,000 rpm in a 8 microcentrifuge. The pellet was washed with 70% alcohol and then dried under vacuum and dissolved in 50 μL distilled water and used as template for PCR. PCR amplification. The primers described above were used with thermal cycle conditions 93°C 5 min.(93°C 30 sec.-52°C 60 sec.-72°C 30 sec) repeated 35 times, yielded an approximately 530 base pair (bp) fragment covering the complete gene, encoding for the 17 kDa outer membrane protein and flanking regions. The general chemical conditions for the PCR amplification consisted of a mixture of 1U Taq DNA polymerase (Boehringer, Mannheim) 2.5 μL 10 times buffer supplied with the enzyme, lμL 25mM MgCl2, 2.5μL 2 mM dNTP ' s, 5 pmol of each primer, 1 μL DNA template and double distilled water to 25 μL. The reaction was performed in a Perkin Elmer 9600 thermocycler, and the amplified products were analyzed on a 1.5% agarose (Kodak) gel in 0.5 Tris Borate EDTA (TBE) buffer. Chosen as positive PCR control, was Rickettsia prowazekii purified DNA. As negative controls PCR buffer treated the same way as the ticks were included. The major part of the coding sequence of this gene is shown in Sequence Listing No. 2 and was performed by direct solid phase DNA sequencing. Immobilization of the biotinylated PCR products followed by strand separation and template preparation, was performed with super paramagnetic beads, Dynabeads M-280 Streptavidin (Dynal, Oslo, Norway) . The nucleotide sequence of the 17 kDa OMP gene was determined in both directions by automated solid phase DNA sequencing with the ALF (Automated Laser Fluorescence) system (Pharmacia Biotech, Uppsala, Sweden) . Sequencing was also performed manually with 35 S dATP (Amersham) and Sequenace II (USAB, Ohio) according to the instructions of the suppliers. 9 Example 2: Construction of antigenic rickettsial peptide A theoretical calculation of the antigenic domains was performed using Jameson-Wolf algorithm in the DNA StarData-program. The Jameson-Wolf produces an index of antigenicity by combining values for hydrophilicity (Hoop-Woood H ( <2> 0,5 < 1> 0 <- l> -0,5 <-2>)), Surface Probability (Emini S ( < 1> 1.0 <0>)), Flexibility (Karplans -Shultz F (< 1 > 1.0 <0>)) and the secondary structure predictions of Chou-Fasman (CF (T=2, t= l , 0) and Gamier- Robson (GR(T=2,t= l, 0,3) by the following formula A = 0,3H + 0, 15S + 0, 15F + 0,2CF + 0,2 GR The method produces a graph, see Fig. 1, that indicates putative antigenic sites at peak valued residues. The peak broadening function adds a cascade of 20%, 40%, 60%, 80%, 100%, 80%, 60%, 40%, 20%, the peak value to the nine residue values surrounding each local maximum of the result. In the antigenic index graph, the peptide sequence according to the invention corresponds to the region of amino acids 93- 120, with three high peak residues expressing high antigenicity. This 28 amino acid peptide is disclosed in Sequence Listing No. 1. A confirming method for visualising the antigenicity is the Western blot assay. 5 μL of purified organism was dissolved in a Laemmli solution (4%SDS, 10% 2-mercaptoethanol, 0,5 % bromophenol blue, 0, 125 M Tris hydrochloride (pH 6.8), 25% glycerol) at room temperature, and SDS-PAGE was carried out with a 7.5% separating gel and 3.9 stacking gel. The gel was run in a Mini-Protein II cell (Bio-Rad) at 10 mA in an ice-bath, and protein bands were visualized by Coomassie blue staining. A high-range molecular weight standard (Bio-Rad) was used to estimate the molecular weights of the electrophoretic bands. Another identical gel was transferred to nitrocellulose paper in a Trans-blot apparatus (Bio-Rad) at 50 V for 1 h in an ice bath. Non-specific binding sites were blocked overnight with 5% non-fat dry milk- 10 TBS (lOmM Tris hydrochloride (pH 7.5), 250 mM NaCl, 0,01% Merthiolate). After three 10-min washes in TBS, the nitrocellulose paper was overlaid with antisera from index patient, diluted 1/ 100 in 3% non-fat dry milk-TBS, and rocked for 2 h. Reactive antibodies were detected with 1/200 gamma chain specific anti-human Ig (Bio Merieux, Marcy lEtoile, France) in 3% nonfat dry milk-TBS. After three further washes in TBS, the bound peroxidase was detected with a solution containing 0,015% 4-chloro- l-naphthol, 0,015% hydrogen peroxide, and 16% methanol in TBS. As soon as the bands became visible, the reactions were stopped with repeated washes in distilled water. As a result, a distinct band appears at 17 kD. Example 3: Diagnostic use of the peptide of the invention A diagnostic reagent comprising the antigenic part of said OMP can be used for detecting/ diagnosing/ quantifying antigenic response in humans and other mammals after contact with bacteria closely related to R.helvetica which express a protein comprising the peptide of the invention. The diagnostics can be performed by a variety of methods for example; Indirect immunofluorescense; Enzyme immunoassays; Radio immunoassays Immunodiffusion; Western blot assays ( see example 2). The two Ala-Ala aminoacids in the beginning of the peptide of the invention make the peptide very suitable for coupling to a solid phase. These two hydrophobic aminoacids will reduce unspecific binding and, thereby, improve the sensitivity of the diagnostic test. Serum from an infected patient gave a clear serological response with the diagonostic kit of the invention indicating that R. helvetica caused the infection. The result was verified with PCR and immunohistochemistry. Serum from the same patient has also been shown to react with the peptide of the invention in immunodiffusion experiments. 11 As an alternative, the cellular response can be tested by, for example, an Immuno spot assay. Example 4: Therapeutic use of the peptide of the invention The antigenic part of said OMP could also be used mixed or coupled to an adjuvant (for example Freunds or Iscomes) to be used as a vaccine. The vaccine can either be used therapeutically or prophylactically.

Claims: CLAIMS 1. A peptide comprising the the amino acid sequence as shown in Sequence Listing No. 1. 2. A peptide according to claim 1, which is obtained from natural sources, or produced by synthetic or recombinant means. 3. A gene encoding the peptide according to claims 1 or 2 comprising all variants due to the degeneracy of the genetic code. 4. A diagnostic reagent comprising the peptide according to claims 1 or 2 or immune response generating parts or variants thereof for detecting rickettsiosis. 5. A diagnostic reagent according to claim 4, for detection of infection with Rickettsia helvetica expressing the peptide according to claim 1. 6. A diagnostic reagent according to claim 4 or 5, which is free or bound to lipids or carbohydrates. 7. A diagnostic kit comprising a diagnostic reagent according to claims 4-6. 8. A diagnostic kit according to claim 7, wherein the reagent is in the form of a solution or bound to a solid phase. 9. A diagnostic kit according to claims 6-8 , comprising a labelled anti-Ig antibody for detection of mammalian IgA, IgG or IgM antibodies against an antigen from R. helvetica. 10. A diagnostic kit according to claims 6-9, wherein the mammalian antibodies are comprised in body fluids such as serum, blood, cerebrospinal fluid, tear fluid, seamen or sweat. 11. A diagnostic kit according to claims 6-8, comprising a labelled T cell recognizing agent for detection of rickettsiosis. 12. A diagnostic kit according to claim 1 1, for detection of cellular immune response against an antigen from bacteria closely related to R. helvetica. 13. A vaccine comprising the peptide according to claims 1 or 2 or immune response generating parts or variants thereof for treatment of rickettsiosis. 14 AMENDED CLAIMS [received by the International Bureau on 19 July 1999 (19.07.99); original claim 1 amended; remaining claims unchanged (2 pages)] 1. A peptide consisting essentially of the the amino acid sequence as shown in Sequence Listing No. 1. 2. A peptide according to claim 1 , which is obtained from natural sources, or produced by synthetic or recombinant means. 3. A gene encoding the peptide according to claims 1 or 2 comprising all variants due to the degeneracy of the genetic code. 4. A diagnostic reagent comprising the peptide according to claims 1 or 2 or immune response generating parts or variants thereof for detecting rickettsiosis. 5. A diagnostic reagent according to claim 4, for detection of infection with Rickettsia helvetica expressing the peptide according to claim 1. 6. A diagnostic reagent according to claim 4 or 5, which is free or bound to lipids or carbohydrates. 7. A diagnostic kit comprising a diagnostic reagent according to claims 4-6. 8. A diagnostic kit according to claim 7, wherein the reagent is in the form of a solution or bound to a solid phase. 9. A diagnostic kit according to claims 6-8 , comprising a labelled anti-Ig antibody for detection of mammalian IgA, IgG or IgM antibodies against an antigen from R. helvetica. 15 10. A diagnostic kit according to claims 6-9, wherein the mammalian antibodies are comprised in body fluids such as serum, blood, cerebrospinal fluid, tear fluid, seamen or sweat. 1 1. A diagnostic kit according to claims 6-8, comprising a labelled T cell recognizing agent for detection of rickettsiosis. 12. A diagnostic kit according to claim 11 , for detection of cellular immune response against an antigen from bacteria closely related to R. helvetica. 13. A vaccine comprising the peptide according to claims 1 or 2 or immune response generating parts or variants thereof for treatment of rickettsiosis.

Inventors: NILSSON KENNETH, PAAHLSON CARL, NILSSON, KENNETH, PAAHLSON, CARL
Applicants: NILSSON KENNETH, PAAHLSON CARL, NILSSON, KENNETH, PAAHLSON, CARL
Application year: 1999
Main classification: C07K14
IPC codes: A61K39, C07K14